Clinical Trial: IPI-926 Extension Protocol for Continuation of Treatment With IPI-926

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: IPI-926 Extension Protocol for Continuation of IPI-926 Treatment in Patients Experiencing Clinical Benefit While Enrolled in an IPI-926 Protocol

Brief Summary: A treatment protocol that enables patients to have continued access to IPI-926.

Detailed Summary:

The extension protocol is a continuation of treatment with IPI-926, as administered to each individual patient during participation in their original IPI-926 protocol.

Patients who are completing their participation in the original IPI-926 protocol in which they enrolled, as defined in the original protocol, and, have stable disease or confirmed complete or partial response as defined by the original protocol may continue to receive treatment with IPI-926 in the extension protocol.


Sponsor: Infinity Pharmaceuticals, Inc.

Current Primary Outcome: Incidence of adverse events (AEs) and serious adverse events (SAEs), and laboratory test results [ Time Frame: Up to 30 days after the last patient study visit ]

Monitoring of AEs, including SAEs as well as review of laboratory sample test data to assess safety and tolerability of IPI-926


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Infinity Pharmaceuticals, Inc.

Dates:
Date Received: May 29, 2012
Date Started: March 2012
Date Completion:
Last Updated: November 13, 2012
Last Verified: November 2012